Elevated S100A8 and/or S100A9 levels in male NSCLC and subtype patients, smokers, and those with advanced disease correlate with survival outcomes, suggesting their potential as prognostic markers (130–132). Here, S100A8 is linked to non-small cell lung carcinoma.